Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Hexarelin

Examorelin, HEX

Quick Stats
Studies 233
Trials 61
Score 2
2000 pubmed

Hexarelin, a growth hormone secretagogue, protects the isolated rat heart from ventricular dysfunction produced by exposure to calcium-free medium.

Rossoni. G G; Locatelli. V V; Müller. E E EE; Berti. F F

Key Findings

  • A 7‑day sub‑cutaneous hexarelin regimen reduced heart injury from calcium‑paradox in isolated rat hearts.
  • The protective effect was independent of changes in plasma or heart IGF‑1, indicating it’s not due to classic growth‑hormone pathways.
  • Acute perfusion of hexarelin into the heart did not confer protection, suggesting prolonged exposure is required.

Practical Outcomes

  • For biohackers, the data imply that short‑term or single‑dose hexarelin is unlikely to give heart‑protective benefits. Any potential cardioprotective effect would probably need several days of continuous dosing, and the relevance to humans is unproven, so caution and further research are needed before considering it in a longevity protocol.

Summary

In rats, giving the peptide hexarelin under the skin for a week helped protect heart tissue from damage caused by a sudden return of calcium, but a single dose directly into the heart did not work. This protection didn't come from higher growth hormone or IGF‑1 levels, and the exact way it works is still unclear.

Abstract

The effect of hexarelin, a potent synthetic growth hormone (GH)-secretagogue, and of human GH were studied on the mechanical and metabolic changes elicited by the calcium-paradox phenomenon in isolated rat hearts submitted to 5 min Ca(2+)-depletion followed by reperfusion with reintegrated Ca(2+)medium. Hexarelin, (80 microg kg(-1)s.c.) administered to normal male young rats for 3 and 7-day, time-dependently antagonized the sudden increase in resting tension of the isolated perfused hearts upon Ca(2+)-repletion. The beneficial effect of hexarelin was particularly evident in the 7-day treatment. In this instance, ventricular contraction peaked at 30 +/- 2 mmHg (controls, 76 +/- 7 mmHg) and the recovery of left ventricular developed pressure (LVDP) was two times higher (P<0.001) than that recorded in controls (LVDP, 29 +/- 2 mmHg). Moreover, the release of creatine kinase into the heart effluent during Ca(2+)-repletion was reduced by 40% (P<0.001) as compared to controls. The protecting activity of hexarelin against the damage induced by calcium-paradox in the heart was apparently divorced from any stimulation of the GH/insulin-like growth factor (IGF) axis, since plasma and heart concentrations of IGF-1 were similar to those measured in control rats. In contrast to hexarelin, administration of GH (400 microg kg(-1) s.c.) for 7 days did not affect the mechanical and metabolic manifestations of calcium-paradox in the perfused rat hearts. Hexarelin (8 microg ml(-1)) perfused for 60 min through the hearts in recirculating conditions did not modify heart contractility and failed to prevent ventricular hypercontractility developed on Ca(2+)-readmission. In conclusion, the mode of action of hexarelin in protecting the rat heart from calcium-paradox events is presently unknown; it would seem, however, that only prolonged exposure to hexarelin makes myocardial cells competent to maintain cytoplasmatic electrolyte balance and to control of Ca(2+)gain, two functions that are impaired during the 'calcium-paradox' phenomenon.

Study Information

Provider

pubmed

Year

2000

DOI

10.1006/phrs.2000.0665